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Introduction
Despite progress in diagnostic technology, the confirmation 
of etiology of community-acquired pneumonia (CAP) and 
community-acquired meningitis (CAM) is still far from 
optimal accuracy and  turn-around time. Pneumonia has the 
highest hospitalization and mortality rate among all infections 
diagnosed in the adult population in the United States (US) [1]. 
Every year, 4,000 cases of bacterial meningitis are reported 
nationwide with 12% fatality rate and up to 34% of cases 
resulting in permanent disability among survivors [2, 3]. These 
serious complications prompt the initiation of antibiotic therapy 
in patients with presumptive bacterial CAP or CAM regardless 
of ability to identify the culprit pathogen. 
The causative pathogen of CAP in hospitalized patients in the 
US remains unknown in up to 62% and on a lower scale in 
CAM [4]. The main diagnostic tools used for evaluation of CAP 
and CAM are microbiologic cultures; which have a relatively 
low yield. Hospitalized patients with CAP have positive blood 
cultures in less than 14% [5, 6]. The sensitivity of sputum culture 
for pneumococcal pneumonia is 60% [7]. The CSF cultures 
performed for CAM are positive in 70-85% cases however 
it takes an average of 48 hours to obtain the result. Although 
cerebrospinal fluid (CSF) Gram stain can identify the pathogen 
in 60-90%, this is only true for CSF with high bacteria load. The 
sensitivity drops to 25% for CSF with colony forming unit (CFU) 
≤10³ [8]. Furthermore, if microbiology material is collected 
after initiation of antibiotic therapy the CSF culture sensitivity 
rate even further decreases.
The uncertainty of the etiology of both CAP and CAM leads to 
empiric treatment and this has become the standard practice. 
This standard practice results in overuse of broad spectrum 
antimicrobials, increasing antibiotic resistance and risk for
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Abstract
Background: The etiologic diagnosis of community acquired pneumonia (CAP) and community-
acquired meningitis (CAM) are still far from optimal accuracy and turnaround time. The most common 
bacterial pathogen identified in both CAP and CAM is Streptococcus pneumoniae. 
Methods: We reviewed the literature on S. pneumoniae antigen to highlight opportunities to optimize 
its use as a point of care diagnostic test to maximize quality of patient care, antimicrobial stewardship 
outcomes and cost saving. A PubMed search was performed using key words “S. pneumoniae 
antigen; rapid diagnostic tests for S. pneumoniae”. We selected articles in English and sorted into 
randomized controlled trials (RCT), case control, and retrospectives studies. 
Results: The BinaxNOW S. pneumoniae antigen rapid immunochromatographic test (ICT) to detect 
C-polysaccharide cell wall antigen was approved by the Food and Drug Administration (FDA) in 
2003.  This test has a turn around time of 15 minutes, a sensitivity of 52-82% and specificity of 89.7-
99.7% in urine and 95.4-100% and 99.3-100% respectively in cerebrospinal fluid (CSF) specimens. 
BinaxNOW detected the antigen in 100% of blood culture bottles that grew S. pneumoniae. S. 
pneumoniae urinary antigen has a sensitivity of 77-92% in bacteremic pneumococcal pneumonia 
and 52-78% non-bacteremic pneumococcal pneumonia. This test was reported to be inexpensive 
and useful in streamlining antibiotic treatment. In a physician survey, this test led to a narrowed 
antibiotic regimen, shorter duration of antibiotics treatment and fewer diagnostic tests. 
Conclusion: S. pneumoniae ICT urinary antigen has an optimal yield to support the etiologic 
diagnosis of CAP and up to 15-minute turnaround time that could facilitate he selection of a one-
antibiotic regimen upon the hospital admission of a patient with CAP. Similarly, S. pneumoniae CSF 
antigen test should be considered a standard test for the evaluation of patients with meningitis.
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medication side effects including the deadly epidemic of C. 
difficile colitis [9]. The median length of stay (LOS) for CAP is 
3 days [5]. In 2011 the cost of all CAP hospitalizations exceeded 
$10 billion [10]. Studies have already shown that de-escalation 
of antibiotics in hospitalized CAP cases is associated with 
decreased LOS without adversely affecting outcomes including 
mortality rate [11, 12]. The most common bacterial pathogen 
identified in both CAP and CAM is S. pneumoniae [3, 4]. Rapid S. 
pneumoniae c-polysaccharide antigen test (SPCAT) BinaxNOW 
has been approved by the Food and Drug Administration 
(FDA) to detect the antigen in the urine samples for diagnosis 
of pneumococcal pneumonia and  in CSF for pneumococcal 
meningitis.
Methods
We reviewed the literature on S. pneumoniae antigen to highlight 
opportunities to optimize its use as a point of care diagnostic 
test to maximize the quality of patient care, antimicrobial 
stewardship outcomes and cost savings. A PubMed search was 
performed using key words “S. pneumoniae antigen; rapid 
diagnostic tests for S. pneumoniae“. We selected articles in 
English and sorted them out in Randomized controlled trials 
(RCT), case control, and retrospectives studies.
Results
Molecular properties of S. pneumoniae antigen. 
S. pneumoniae are lancet shaped Gram-positive bacteria that 
grow in pairs or short chains. Their pathogenicity is attributed 
to many structures, most of them located on the surface. Three 
major surface layers have been found; the capsule, the cell wall, 
and the plasma membrane [13, 14]. 
The capsule is made of a high molecular weight polymer 
units of repeating oligosaccharides. There may be additional 
components to this like acidic components or phosphorylcholine 
(PC) [15]. Based on differences in the capsular polysaccharide 
(PS), pneumococci are sorted out into 90 plus serotypes [16]. 
This has been recognized as a major virulence factor as it has 
been found that encapsulated strains have 105 times more 
virulence than non-encapsulated. Also, there is 50% difference 
in lethal dose between capsulated and non-encapsulated strains 
[13] [17].
The cell wall is mainly composed of peptidoglycan which is 
glycan chains cross-linked through peptide side chains. A 
complex teichoic acid containing PC residue known as cell wall 
polysaccharide (CWPS) is attached to peptidoglycan via N-acetyl 
muramic acid[18].  CWPS has various proposed mechanisms 
of virulence like inducing inflammation via activation of the 
alternative complement pathway, enhancement of vascular 
permeability, mast cell degranulation, polymorphonuclear 
leukocytes (PMN) activation and IL-1 production increase [19-
21].
Capsular polysaccharide antigens of S. pneumoniae were first 
detected in urine of patients with pneumonia in 1917 [22]. The 
latex agglutination test was initially developed to detect urinary 
capsular polysaccharide of S. pneumoniae but the test was of 
limited usefulness because it was not easy to perform and could 
not detect all the different capsule serotypes [23]. Schaffner 
et al. used enzyme-linked immunosorbent assay (ELISA) for 
detection of this capsular polysaccharide in urine and found 
that the levels of this antigen varied depending on the severity of 
infection as well as the serotype of the bacteria. Notably, there is 
more than 250 fold variation in serotype-specific clearance rates 
[24].
Later in 2003, the FDA approved BinaxNOW S. pneumoniae 
assay, a rapid immunochromatographic test (ICT) detecting 
CWPS antigen that has shown good utility for diagnosis of 
S. pneumoniae via urine with high sensitivity and specificity 
[25]. The high analytical sensitivity for CWPS antigen urine 
specimens make it the point of care test [26]. Some of the 
advantages that S. pneumoniae ICT antigen offers is that it is 
easy to perform in all settings with 15 minutes turnaround 
time, the test is not serotype dependent and prior antibiotic use 
has less influence on the diagnostic yield [25] [26]. In a study 
by Said et al, prior antibiotic use has shown reduction in the 
relative diagnostic yield for S. pneumoniae ICT antigen only by 
26%, sputum cultures by 34%, blood cultures by 67% [27].
S. pneumoniae antigen as the FDA-approved and non-
approved diagnostic test 
Though S. pneumoniae is a common pathogen in hospitalized 
patients with CAP, its microbiological diagnosis remains 
challenging. Conventional tests that have been used to identify 
the etiology of pneumonia include Gram stain of sputum, 
sputum cultures, and blood cultures. Other tests like latex 
agglutination, counter-immunoelectrophoresis that detect 
pneumococcal capsular antigens, have poor sensitivity and 
specificity [28]. They are not considered as useful diagnostic 
techniques in clinical practice. The ICT BinaxNOW has been 
cleared by the FDA to detect the pneumococcal antigen in both 
the urine and the CSF samples. It detects the pneumococcal 
C-polysaccharide present in the cell wall that is common to all 
serotypes [29]. 
Testing is not recommended in individuals vaccinated against 
pneumococcus in the last 5 days. S. pneumoniae ICT antigen 
was approved as an adjunct to culture for presumptive 
diagnosis of pneumococcal pneumonia. The most widely used 
indirect detection method for S. pneumoniae is the detection of 
pneumococcal antigen in urine.
Wellcogen bacterial antigen test is another simple rapid 
test. This test utilizes a solid phase coated with polyclonal 
antibody to detect antigen in the human urine sample. This is 
a latex agglutination test runs with antibody coated polystyrene 
beads that agglutinate in the presence of sufficient antigen. S. 
pneumoniae ICT antigen has also been detected in other body 
fluids like blood, pleural effusion or sputum samples. The FDA 
has not approved any of them yet as a standard of practice. 
Several studies showed the promising results of S. pneumoniae 
antigen ICT in blood (Table 1.) The test sensitivity and specificity 
in blood samples were 87.1-100% and 96.9-100% respectively 
revealing higher diagnostic yield than the urinary antigen. In 
pleural effusion, the S. pneumoniae ICT antigen resulted in a 
sensitivity of 79-88% and specificity of 71-93.6%; which should 
be considered as a valuable diagnostic tool in clinical practice.
 
Discussion
We strongly believe that physicians should consider the best 
utilization and the missing diagnostic opportunities of S. 
pneumoniae ICT antigen when serving patients with CAP 
and CAM. The determination of the etiologic agent for the 
pneumonia is essential to maximize the selection of an effective 
narrowed spectrum antibiotic treatment aiming to prevent the 
risks of adverse effects and antimicrobial resistance [30, 31]. 
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Table 1. Diagnostic test performance of S. pneumoniae 
C-polysaccharide antigen
The SPCAT in urine and CSF support the etiological diagnosis in 
in patients with S. pneumoniae pneumonia and CAM. In adult 
patients, the SPCAT in urine was reported to have a sensitivity 
of 50-80% in cases without bacteremia and 75-85% in those 
with bacteremia; the specificity is approximately 95%; the use of 
concentrated urine by selective ultrafiltration slightly increases 
the sensitivity of the test [32].
The IDSA guidelines from 2007 recommend SPCAT combined 
with at least blood culture for all patients with CAP with 
suspected pneumococcal etiology and at least one of the 
following risk factors: failure of outpatient management, ICU 
admission, leukopenia, active alcohol abuse, chronic severe 
liver disease, asplenia or pleural effusion. A meta-analysis from 
papers published from 1996 to 2012 showed that higher pooled 
sensitivity and specificity of of the S. pneumoniae ICT urinary 
antigen testcompared to culture supporting its use as part of the 
workup for diagnosis of community acquired pneumonia [33]. 
In multiple studies, the urine S. pneumoniae assay has shown 
higher sensitivity for bacteremic pneumococcal pneumonia a 
(77-92%) than for non-bacteremic pneumococcal pneumonia 
(52-78%) [34, 35]. The indication of SPCAT in Healthcare 
Associated Pneumonias (HCAP) is controversial, and it is not 
recommended [36, 37]. With increasing concern regarding 
antibiotic stewardship, the ability to safely and quickly narrow 
antibiotic therapy becomes crucial. Physicians are encouraged 
to target antibiotic therapy towards S. pneumoniae even if 
the S. pneumoniae urinary antigen ICT is the only positive 
microbiologic test and there is no evidence of any other etiology. 
The underutilization of S. pneumoniae urinary ICT or CSF 
antigen ICT test may lead to a suboptimal outcome in terms 
of recovery. This leads to increased risk of antibiotic related 
complications like C. difficile diarrhea in those receiving 
broad spectrum antibiotics that could have been obviated by 
early diagnosis and treatment. According to a multi-hospital 
observational study from 2016, S. pneumoniae urinary antigen 
ICT is an inexpensive, noninvasive test that favorably influences 
antibiotic prescribing practices [38]. The costs were reduced 
significantly as the regimens of antibiotics were changed based 
on the S. pneumoniae urinary antigen ICT result [39]. In a 
survey in 2013 among Physician IDSA members, the result 
of S. pneumoniae urinary antigen ICT led to 84% narrowed 
antibiotic regimen, 28% shortened the course of antibiotics, and 
67% ordered fewer diagnostic tests [40].
The growing emergence of antibiotic resistant organisms is 
a major public health and financial burden. The use of rapid, 
non-invasive S. pneumoniae ICT urinary antigen may favorably 
influence antibiotic prescribing practices. Thus, S. pneumoniae 
ICT urinary antigen can guide to safely de-escalate antibiotics 
once a positive result is obtained [30]. 
The BinaxNOW S. pneumoniae antigen test detected 
pneumococcal antigen in 100% of blood culture bottles that 
grew S. pneumoniae. False positive reactions were seen due to 
cross reactivity of polysaccharide antigen with S. mitis group 
[41].
Marcos et al. found that SPCAT testing in concentrated urine 
was positive in 70% of the patients with pneumococcal CAP 
proven by both culture and SPCAT 1 month after the diagnosis 
of CAP despite good clinical, laboratory and radiographic 
evolution. Therefore, further studies are needed to ascertain 
how long positive SPCAT results may persist after an episode 
of pneumococcal CAP to properly interpret the ICT test in 
clinical practice which will be of clinical significance especially 
in individuals who have recurrent pneumonia. They also found 
that five patients (11.1%) with bacteremic pneumococcal CAP 
tested SPCAT positive, only after concentrating the urine, which 
supports the necessity to concentrate the urine for this test [30]. 
One of the limitations of our review is that this is not a meta-
analysis compiling the statistical data results. However, as part 
of the strengths of our paper is the systematic review of papers 
published in PubMed in the order of RTC, case-control studies 
and retrospective study. 
Conclusion
The S. pneumoniae ICT urinary antigen is likely the best test 
to support the etiologic diagnosis of CAP with the optimal 
sensitivity and up to 15 minutes turn around result allowing to 
streamline the antibiotic de-escalation. The S. pneumoniae CSF 
antigen test, this test has optimal sensitivity and turnaround 
time; which should be considered a standard test for the 
evaluation of patients with meningitis.
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